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Introduction
The synthetic oleanane triterpenoid 2-cyano-3,12-diox-
ooleana-1,9-dien-28-oic acid (CDDO) and its derivatives 
1[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole 
(CDDO-Im) and methyl 2-cyano-3,12-dioxooleana-1,9(11)
dien-28-oate (CDDO-Me) have been shown to protect against 
oxidative stress in various cell and animal models1–5 and exhibit 
anti-inflammatory properties.6 In addition, these 2 compounds 
have been shown in some studies to provide a chemopreventive 
effect against certain tumors, largely by reducing the viability of 
these cells.7–10 Comparing these 2 structurally different forms 
of CDDO, we previously determined that there is a similar 
degree of cytoprotection between the 2 compounds; however, 
significant differences in gene expression were seen between 
the 2 following a 6-hour treatment on human umbilical vein 
endothelial cells (HUVEC).11 The derivative CDDO-Im was 
shown to induce more gene expression changes than 
CDDO-Me and resulted in significantly higher expression 
levels of key cytoprotective genes, including heme oxygenase 1 
(HMOX1).11
Both CDDO-Im and CDDO-Me have been shown to 
elicit protective effects largely through the activation of the 
transcription factor nuclear factor erythroid 2–related factor 2 
(NRF2).12–14 Our previous work with CDDO-Im and 
CDDO-Me supported published work that demonstrated the 
central role of NRF2 in homeostasis11,15 and its role in HMOX1 
induction; in addition, it identified potentially new genes that 
provide additional cytoprotection. A recent study evaluated the 
kinetics of HMOX1 induction by 4 different transcription fac-
tors (HSF-1, AP-1, NRF2, and NF-κB) and showed that they 
differ in their mechanism of action and kinetics of inducing 
HMOX1.16 That study highlighted the need for a better under-
standing of protective mechanisms of action that accurately 
takes into account the temporal nature of gene response over 
time; through the use of mathematical modeling, the study 
revealed multiple pathways for HMOX1 induction. The study 
presented here expands on that approach by studying tran-
scriptional kinetics of a relevant system that not only allows for 
modeling with experimentally derived data but also extends the 
study of mechanism of action by using further analysis to iden-
tify upstream initiators of observed gene expression.
The CDDO-Im cytoprotection of HUVEC was investi-
gated by studying gene expression over a time course (0.5, 1, 3, 6, 
and 24 hours). The purpose of this study was to determine 
whether alterations in gene expression induced by CDDO-Im 
over time, particularly at early time points, could uncover the 
proximal mechanism responsible for the cytoprotective effect.11,15 
In addition, analysis with Expression2Kinases (X2K) was used 
to identify transcription factors, kinases, and complexes that 
drive changes in global gene expression.17 Expression2Kinases 
integrates chromatin immunoprecipitation (ChIP)-seq/chip 
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and position weight matrix data, protein-protein interactions, 
and kinase-substrate phosphorylation reactions to better identify 
regulatory mechanisms upstream of genome-wide differences in 
gene expression.
Observing and measuring temporal changes provide for a 
better understanding of dynamic responses and provide insight 
into the actual regulatory mechanisms responsible for cytopro-
tection; critical processes required for downstream initiation of 
cytoprotective genes will be investigated by focusing on early 
time points. This study also sought to provide methods that 
allow for the discovery of mechanisms of action involved in 
cytoprotection from CDDO-Im in an approach that can be 
applied to other drug model systems.
Materials and Methods
Chemicals and reagents
The derivative CDDO-Im (96% purity) was purchased from 
Toronto Research Chemicals Inc. (Toronto, ON, Canada). 
Dimethyl sulfoxide (DMSO) was from Sigma-Aldrich (Saint 
Louis, MO, USA).
Cell culture
Stock cultures of gender-mixed HUVEC (Lifeline Cell 
Technology, Walkersville, MD, USA) pooled from 10 different 
donors were cultivated on T75 flasks (Corning Inc., Corning, 
NY, USA) in MCDB 131 medium at 37°C in a humidified 
atmosphere of 92% nitrogen, 3% oxygen, and 5% CO2 with 
medium changes every 2 days until confluence is reached.18,19 
MCDB 131 medium, trypsin/EDTA, and antibiotic/antimy-
cotic were obtained from Life Technologies (Carlsbad, CA, 
USA). Endothelial supplements were obtained from American 
Type Culture Collection (ATCC, Manassas, VA, USA). Prior 
to an experiment, HUVEC were subcultivated with trypsin/
EDTA onto Costar 96-well or 12-well multiplates (Corning 
Inc.) at 5000 cells/cm2, grown to confluence, and kept for 72 
hours to produce a quiescent cell layer. Only the second through 
fifth population doublings of cells were used as described in a 
study by Wang et al.20 The derivative CDDO-Im was diluted 
(1000-fold) after dissolving in DMSO (0.1%) with medium to 
a final concentration of 200 nM. Human umbilical vein 
endothelial cells were grown to confluence at which time they 
were pretreated with CDDO-Im for their respective incuba-
tion times (0.5, 1, 3, 6, and 24 hours). Gene expression profiling 
of CDDO-Im–treated HUVEC was compared with vehicle 
control (0.1% DMSO).
Total RNA isolation
RNA from cultured HUVEC grown on multiplates was 
extracted using TRI reagent according to the manufacturer’s 
instructions (Molecular Research Center, Cincinnati, OH, 
USA) as previously described.15 Using a NanoDrop ND-1000 
Spectrophotometer (NanoDrop Technologies, Wilmington, 
DE, USA), RNA yield was quantified and its quality assessed 
by electrophoresis on 1% agarose gels containing 1:10 000 
SYBR Gold in the loading buffer (Invitrogen, Carlsbad, CA, 
USA). The resulting gels were scanned with a Kodak Image 
Station 2000R Digital Imaging System and the resulting digi-
tized image scanned with NIH Image to determine the density 
in each band. The ratio of 28S to 18S was 2 to 1, indicating 
high-quality RNA.
Quantitative real-time polymerase chain reaction
Complementary DNA (cDNA) was prepared from 1 µg of 
total RNA from each sample using the High-Capacity cDNA 
Archive Kit (Life Technologies, Grand Island, NY, USA). 
Real-time polymerase chain reaction (RT-PCR) was per-
formed on a Roche LightCycler 480 thermal cycler (Roche 
Diagnostics, Indianapolis, IN, USA) with Roche LightCycler 
TaqMan Master Kit (Roche Diagnostics) for confirmation 
of microarray results. The 18S primer/probe was used as an 
endogenous control for each sample and measured simultane-
ously with each labeled sample for the purpose of normaliza-
tion; relative quantification was determined by the comparative 
CT method.21 Primer/probes of interest ( JUNB, FOS, DUSP1, 
and EGR3) and 18S primer sets were purchased from TaqMan 
Gene Expression Assays (Applied Biosystems, Foster City, 
CA, USA). Dimethyl sulfoxide–treated (vehicle) HUVEC at 
time 0 were used as the comparator for all CDDO-Im–treated 
samples.
Polyacrylamide gel electrophoresis and Western 
blotting
Protein was isolated from the HUVEC after incubation with 
CDDO-Im (200 nM) for each of the time points represented 
in the microarray experiment (0.5, 1, 3, 6, and 24 hours), by 
addition of 50 µL of lysis buffer (Life Technologies) containing 
10 mM Tris (carboxyethyl) phosphine hydrochloride (Sigma-
Aldrich). About 15 µL, containing approximately 5 µg of pro-
tein, from each treatment was run on E-PAGE 96-well 6% 
gels (Life Technologies) and then transferred to a nitrocellu-
lose membrane (Life Technologies). After blocking in blocking 
buffer (LI-COR Biosciences, Lincoln, NE USA), the blots 
were then incubated with rabbit HMOX1, HSP105, DUSP1, 
DYRK3, or HSP70 primary antibodies (1:5000; Assay Designs 
Inc., Ann Arbor, MI, USA) for 1 hour. In addition, each blot 
was dual-labeled with β-actin as a loading control that was 
used for normalizing antibody intensity of each protein of 
interest. The blots were washed 3 times with 0.1% Tween 20 in 
phosphate-buffered saline and incubated with donkey anti-
rabbit secondary antibody (LI-COR Biosciences) for 30 min-
utes before 3 more washes and then allowed to dry for 
visualization. Visualization was performed using the Odyssey 
Imaging System (LI-COR Biosciences) that allowed for dual 
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labeling of 2 different proteins and was quantified by direct 
measurement of background-subtracted infrared florescent 
signals.
Gene expression analysis
RNAs (500 ng) from 4 replicates for each time point (0.5, 1, 3, 
6, and 24 hours) were labeled following Agilent’s Low RNA 
Input Linear Amplification Kit (Agilent, Santa Clara, CA, 
USA). All sample labeling, hybridization, washing, and scan-
ning steps were conducted according to the manufacturer’s 
specifications. For each group, 200 ng of complementary RNA 
from each labeling reaction was hybridized to the Agilent 
Whole Human Genome Oligo Microarray (Agilent). The 
Whole Human Genome Oligo Microarray is in an 8× 60K 
slide format and microarray interrogates all known genes. After 
hybridization, the slides were washed and then scanned with 
the Agilent G2505C Microarray Scanner System (Agilent). 
The fluorescence intensities on scanned images were extracted 
and preprocessed by Agilent Feature Extraction Software. 
These data have been submitted to the Gene Expression 
Omnibus under accession no. GSE71622.
Statistical analysis
Microarray data analysis and statistical analysis were performed 
with BRB-ArrayTools.22 Genes were considered statistically 
significant with P < .001 and false discovery rate value of <5%. 
Filtered data analyzed by BRB-ArrayTools were submitted to 
GeneMANIA for network analysis. This program represents 
the complexity of biological regulatory systems as networks 
whose topology provides a manageable technique for analyzing 
the principal components of a complex system.23–25
Principal components (genes or proteins) are nodes, and 
interactions are depicted as edges.24 Similar patterns of expres-
sion were observed between certain individual time points after 
BRB-ArrayTools analysis and were consolidated into early (0.5 
and 1 hour), intermediate (3 and 6 hours), and late (24 hours) 
defined groups for more consistent representation of the global 
expression response over time. Western blot data are presented as 
the mean ± SD. A 2-class comparison was performed to identify 
genes that were differentially expressed using a random-variance 
t test (http://linus.nci.nih.gov/BRB-ArrayTools.html).22
X2K analysis
The immediate-early time-course gene expression data (30 min-
utes and 1 hour) were submitted to X2K to identify upstream, 
proximal regulators likely responsible for later observed patterns 
of genome-wide gene expression.17 The most likely transcription 
factors that regulate the differences in gene expression are 
inferred, then known protein-protein interactions are connected 
to the identified transcription factors using additional proteins 
for building transcriptional regulatory subnetworks centered on 
these factors, and finally, kinase-substrate protein phosphoryla-
tion reactions are used to identify and rank candidate protein 
kinases that most likely regulate the formation of the identified 
transcriptional complexes.
Results
Time-course gene expression profiling of CDDO-
Im reveals different phases of response
Gene expression profiling of CDDO-Im treated for 0.5, 1, 3, 6, 
and 24 hours was performed using Agilent Whole Human 
Genome Microarrays. A heat map of genes statistically altered 
in their expression upregulated or downregulated more than 
8-fold across the time following clustering is shown in 
(Figure 1). The derivative CDDO-Im induced genes as quickly 
as 0.5 hour, including genes involved in early growth response 
(EGR1, EGR2, and EGR3) as well as genes such as FOS (regu-
lators of cell proliferation, differentiation, and transformation 
in the early phases [0.5-1 hour] of gene expression response 
induced by CDDO-Im (Table 1)). These genes were rapidly 
upregulated by 0.5 hour and in several cases returned to near 
basal levels by 3 hours (Figure 1).
Genes identified in the intermediate phase (3- and 6-hour 
expression levels) of the global gene expression analysis 
included known protective-related genes such as HMOX1, 
NQO1, HSPA1A, HSPA1B TAGLN, SRXN1, PTPRU, and 
UNC5B. Table 2 lists the top 10 most highly expressed genes 
in this intermediate phase (3-6 hours). Several of these genes, 
as illustrated in Table 3, are directly related to the NRF2  
or Antioxidant Response Element (ARE) pathways and are 
known to be downstream protective genes induced through 
signaling and phosphorylating events.
Expression of genes at 24 hours served as a reference for 
activity of early initiated gene expression in response to 
CDDO-Im treatment and included TIMP3, CXCR4, and 
TFEC, among others, which largely resembled the control 
(DMSO-treated) gene expression profile (Table 4).
Profiling reveals peak times for maximal protection 
provided by NRF2-mediated genes
Examining the results over time showed the time point at 
which maximal expression is achieved. Early genes such as 
JUNB and FOS exhibit rapid increases in gene expression (7.81 
and 45.26, respectively) at the 0.5-hour time point (Table 1). 
Other NRF2-mediated genes, such as HMOX1 and NQO1, 
obtain peak expression later in the time course (7.96 at 3 hours 
for HMOX1 and 4.52 at 24 hours for NQO1) (Table 2).
RT-PCR and Western blotting confirm microarray 
gene expression profiles
To validate the microarray results, quantitative RT-PCR was 
performed on several immediate-early key genes at 0.5, 1, and 
4 Gene Regulation and Systems Biology 
Figure 1. Hierarchical agglomerative clustering of genes exhibiting more than an 8-fold statistical alteration in expression (false discovery rate < 10%) 
based on Pearson correlation coefficient.
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3 hours. The results confirmed that genes such as JUNB, FOS, 
DUSP1, and EGR3 were rapidly induced by 0.5 hour and back 
to gene expression levels comparable with controls (DMSO) 
by 3 hours (Figure 2). To investigate translation of protein 
products over the time course, Western blotting was performed 
on several of the significantly expressed genes. Figure 3 shows 
protein expression for HSP105, DYRK3, DUSP1, HSP70, and 
HMOX1 at 1, 3, and 6 hours. HMOX1 showed 2-, 3-, and 
12-fold increases in protein expression compared with DMSO 
at 1, 3, and 6 hours, respectively (P < .05) for all time points. 
HSP105 showed 1.2-, 1.4-, and 4.7-fold increases compared 
with DMSO (P < .05). DUSP1 exhibited protein expression 
levels that were all close to 1-fold increase compared with 
DMSO whose protein expression levels were consistent with 
messenger RNA (mRNA) levels from the microarray with the 
exception of 0.5 hour. DYRK3 had small but significant 
increases in mRNA levels in the gene expression profiles; this 
finding was confirmed by protein expression levels (1.0-, 1.3-, 
1.8-fold) compared with DMSO (P < .05). HSPA1A showed 
similar trend such that the protein expression levels exhibited 
small increases over the time course (1.2, 1.4, and 1.6; P < .05). 
The mRNA expression levels obtained from the microarray 
analysis for HSPA1A at the same time points (1, 3, and 6 hours) 
were 0.74-, 2.1-, and 4.8-fold increased, respectively.
Table 1. Top 10 most highly expressed genes in the “early” phase (0.5-1 hour) of induction resulting from treatment with a 200-nM dose of CDDO-
Im in HUVEC.
SyMBOl NAME 0.5 H 1 H 3 H 6 H 24 H
EGR3 Early growth response 3 80.6 42.4 1.6 0.3 0.3
NR4A1 Nuclear receptor subfamily 4, group A, member 1 63.9 22.9 0.6 0.4 0.4
FOS FBJ murine osteosarcoma viral oncogene homolog 45.3 7.0 4.2 1.5 1.2
EGR2 Early growth response 2 26.1 10.8 0.8 0.9 0.2
FOSB FBJ murine osteosarcoma viral oncogene homolog B 23.5 24.3 3.7 1.0 2.8
EGR4 Early growth response 4 15.6 16.9 3.1 1.0 1.0
EGR1 Early growth response 1 8.5 2.1 1.8 1.3 0.4
DUSP1 Dual specificity phosphatase 1 8.4 1.2 0.6 0.9 0.7
KlF4 Kruppel-like factor 4 (gut) 8.1 8.4 1.8 1.0 0.6
JUNB Jun B proto-oncogene 7.8 4.6 1.9 1.2 1.3
Abbreviations: CDDO-Im, 1[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole; HUVEC, human umbilical vein endothelial cells.
Values at each time point represent fold change compared with control (dimethyl sulfoxide vehicle–treated HUVEC at time 0) after normalization to housekeeping genes.
Table 2. Top 10 most highly expressed genes in the “intermediate” phase (3-6 hours) of induction resulting from treatment with a 200-nM dose of 
CDDO-Im in HUVEC.
SyMBOl NAME 0.5 H 1 H 3 H 6 H 24 H
NOG Noggin 12.2 31.5 24.6 0.7 0.7
F3 Coagulation factor III (thromboplastin, tissue factor) 2.9 5.7 9.2 5.6 1.3
DACT1 Dapper, antagonist of β-catenin, homolog 1 (Xenopus laevis) 2.3 8.5 8.2 1.4 0.9
HMOX1 Heme oxygenase (decycling) 1 1.7 5.2 8.0 7.7 6.2
ATOH8 Atonal homolog 8 (Drosophila) 1.9 7.9 7.2 1.4 1.4
ClDN23 Claudin 23 6.1 13.0 5.6 1.4 2.2
HEy1 Hairy/enhancer of split related to yRPW motif 1 43.6 55.7 5.4 0.9 1.2
AlPK2 Alpha-kinase 2 1.8 1.0 5.4 1.0 2.1
FZD7 Frizzled family receptor 7 6.8 20.8 5.3 4.1 0.9
RASl1B RAS-like, family 11, member B 8.4 16.9 5.1 0.9 0.4
Abbreviations: CDDO-Im, 1[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole; HUVEC, human umbilical vein endothelial cells.
Values at each time point represent fold change compared with control (dimethyl sulfoxide vehicle–treated HUVEC at time 0) after normalization to housekeeping genes.
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Correlation of functional and biological 
connectivity using network analysis
To focus on early initiators of the gene expression profile, net-
work analysis was performed on the 0.5-hour samples follow-
ing dosing with 200 nM CDDO-Im. The network graphically 
represents nodes (genes) and edges (the biological relationship 
between genes). This network included genes such as NR4A2, 
FOS, and JUNB; several EGR variations; and identified DUSP1 
as a key immediate-early gene. This class of genes includes 
functions such as early growth stimulation, cell differentiation 
and growth, and signal transduction (Figure 4). Figure 5 dem-
onstrates a network that highlights intermediate gene expres-
sion 3 hours after treatment with CDDO-Im.
X2K reveals key protein kinase events including 
possible role of mitogen-activated protein kinase 
kinase 1
To identify early regulators of cytoprotection provided by 
CDDO-Im, the time-course gene expression study was sub-
mitted to X2K for analysis of transcription factors, intermedi-
ate proteins, and protein kinases that regulate downstream 
induction of cytoprotective genes. Once the expression data 
were submitted for analysis, a list of predicted transcription 
factors was generated.
Using the top predicted transcription factors as seeds for 
building protein complexes, a subnetwork of intermediate pro-
teins were identified; these proteins connect through known 
Table 3. Altered nuclear factor erythroid 2–related factor 2 (NRF2)-mediated gene set.
SyMBOl NAME 0.5 H 1 H 3 H 6 H 24 H
HMOX1 Heme oxygenase (decycling) 1 1.7 5.2 8.0 7.7 6.2
NQO1 NAD(P)H dehydrogenase, quinone 1 0.8 0.7 1.5 2.6 4.5
JUNB Jun B proto-oncogene 7.8 4.6 1.9 1.2 1.3
FOS FBJ murine osteosarcoma viral oncogene homolog 45.3 7.0 4.2 1.5 1.2
DNAJA4 DnaJ (Hsp40) homolog, subfamily A, member 4 0.9 1.2 1.8 1.9 0.9
DNAJB11 DnaJ (Hsp40) homolog, subfamily B, member 11 0.7 0.8 1.1 1.0 0.8
GClC Glutamate-cysteine ligase, catalytic subunit 1.1 0.8 0.7 1.4 1.3
GClM Glutamate-cysteine ligase, modifier subunit 1.0 0.8 1.1 1.4 1.3
This table shows gene expression values in response to 1[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole treatment throughout the time course that are known 
to be mediated through the NRF2-mediated oxidative stress response pathway. Values at each time point represent fold change compared with control (dimethyl sulfoxide 
vehicle–treated human umbilical vein endothelial cells at time 0) after normalization to housekeeping genes.
Table 4. Top 10 most highly expressed genes in the “late” phase (24 hours) of induction resulting from treatment with a 200-nM dose of CDDO-Im in 
HUVEC.
SyMBOl NAME 0.5 H 1 H 3 H 6 H 24 H
GPIHBP1 Glycosylphosphatidylinositol anchored high-density 
lipoprotein–binding protein 1
1.6 2.1 1.8 1.5 12.6
CXCR4 Chemokine (C-X-C motif) receptor 4 1.8 1.1 0.5 0.9 12.0
MAN1C1 Mannosidase, alpha, class 1C, member 1 4.9 5.4 4.0 1.1 9.8
TFEC Transcription factor EC 1.7 0.8 1.7 3.4 7.1
FlJ34503 Uncharacterized FlJ34503 3.5 2.6 1.7 1.0 6.7
AFAP1l2 Actin filament–associated protein 1-like 2 5.1 4.9 2.6 1.6 6.6
TIMP3 TIMP metallopeptidase inhibitor 3 4.8 5.0 3.7 1.1 6.2
SEMA6A Sema domain, transmembrane domain (TM), and 
cytoplasmic domain, semaphorin 6A
5.3 1.6 0.7 0.7 5.9
INHBB Inhibin, beta B 7.7 9.0 2.0 0.7 5.9
APCDD1 Adenomatous polyposis coli downregulated 1 1.6 1.9 0.8 0.6 5.4
Abbreviations: CDDO-Im, 1[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole; HUVEC, human umbilical vein endothelial cells.
Values at each time point represent fold change compared with control (dimethyl sulfoxide vehicle–treated HUVEC at time 0) after normalization to housekeeping genes.
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protein-protein associations to the transcription factors and to 
the known protein kinases involved that phosphorylate the 
protein complexes. Among these predicted kinases, dual speci-
ficity mitogen-activated protein kinase kinase 1 (MAP2K1) 
was identified as playing a compelling early role in the regula-
tion of subsequent gene expression (Figure 6).
Discussion
Time-course gene expression through transcriptomic and pro-
teomic data analysis has increasingly become a plausible 
approach to study cellular responses to stimuli for drug discov-
ery, development, and drug therapeutics.26,27 The technology is 
well suited for the dynamic nature of gene expression over time 
and allows for detailed examination of underlying mechanisms. 
This study highlights a multileveled use of bioinformatics tools 
that incorporate human time-course gene expression data in a 
systems pharmacology approach to illustrate a method for 
detailing mechanisms for observed genome-wide gene expres-
sion patterns.
Time-course gene expression analysis of HUVEC treated 
with 200 nM CDDO-Im revealed distinct phases of gene 
expression as a function of time; the dynamic nature of the 
most significantly expressed genes is illustrated in the cluster-
ing analysis and heat map presented in this work. Of particular 
interest is the early response (0.5 hour), which was key for elu-
cidating mechanisms that drive downstream gene expression 
responses and regulate critical cellular signaling events. To the 
best of our knowledge, this work is the first of its kind to exam-
ine CDDO-Im in HUVEC from a systems pharmacology 
approach using time-course gene expression and applying fur-
ther novel analysis to truly elucidate initiators of upstream gene 
expression.
Analysis of this gene expression data set with integration of 
data obtained from protein-protein interactions and kinase-
substrate phosphorylation reactions showed that CDDO-Im 
initiates rapid responses as early as 0.5 hour and causes early 
key phosphorylation events that lead to activation of several 
initiators of downstream expression. Consistent with our previ-
ous work, as well as others, several genes involved in the NRF2 
pathway were reconfirmed in this study.11,13,15 Many of these 
genes have previously been identified to play crucial roles in 
downstream cytoprotection, but the underlying mechanism 
initiating this response has not been fully elucidated.28,29 This 
Figure 2. Immediate-early gene expression levels induced by 1[2-cyano-
3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole (CDDO-Im) treatment in 
human umbilical vein endothelial cells measured with quantitative 
real-time polymerase chain reaction. JUNB, FOS, DUSP1, and EGR3 
expression levels were significantly increased by 30 minutes after CDDO-
Im treatment compared with dimethyl sulfoxide (DMSO) control (n = 4; *P 
< .001). Gene expression levels for this set of genes were back to levels 
comparable with control (DMSO) by 3 hours.
Figure 3. Protein induction by 1[2-cyano-3,12-dioxooleana-1,9(11)-dien-
28-oyl]imidazole (CDDO-Im) in human umbilical vein endothelial cells by 
relative Western blot analysis for time points 1, 3, and 6 hours. HMOX1, 
HSP105, DUSP1, DyRK3, and HSP70 were all compared with dimethyl 
sulfoxide (DMSO) control (0.1% final concentration). Values are presented 
as mean values with standard deviations (n = 4; *P < .05).
Figure 4. Network of genes constructed by GeneMANIA software on the 
basis of the functional and biological connectivity of genes. This network 
highlights the genes induced by 1[2-cyano-3,12-dioxooleana-1,9(11)-dien-
28-oyl]imidazole after treatment for 0.5 hour and represents the 
immediate-early gene response. The network is graphically represented 
as nodes (genes) and edges (the biological relationship between genes). 
Black nodes represent significantly expressed genes present in the input 
data submitted to GeneMANIA. Gray nodes represent genes returned by 
GeneMANIA. The size of each node is proportional to the degree of 
connectivity within the network, whereas the edge width is proportional to 
the confidence of the connection.
8 Gene Regulation and Systems Biology 
analysis identified a key role provided by MAP2K1, also com-
monly known as MEK1. Mitogen-activated protein kinase 
kinase 1 lies upstream of mitogen-activated protein kinases 
(MAPKs) and regulates this class of kinases through a wide 
variety of extracellular and intracellular signals.30 Mitogen-
activated protein kinases, also known as extracellular signal–
regulated kinases (ERK), are well known to act as initiation 
points for further signaling events.31 Mitogen-activated pro-
tein kinase kinase 1 has been shown to obtain activation 
through events such as the binding of extracellular ligands to 
cell-surface receptors which in turn activates RAS and RAF1.32 
RAF1, through phosphorylation of threonine and tyrosine 
residues of MAP2K1, leads to further activation and transduc-
tion of signaling pathways such as MAPK/ERK. The MAPK/
ERK pathway has widely been reported to mediate biological 
functions, such as survival, cell growth, and metabolism, largely 
through downstream gene transcription.33–35
The identification of the DUSP1 gene through gene expres-
sion analysis (GeneMANIA) of the 0.5-hour time point 
revealed a crucial link in the understanding of the mechanism 
related to CDDO-Im. DUSP1, also known as mitogen-acti-
vated protein kinase phosphatase-1 (MKP-1), is a key phos-
phatase that has recently been shown to be rapidly induced in 
response to several anti-inflammatory drugs including gluco-
corticoids.36 DUSP1 preferentially dephosphorylates both 
threonine and tyrosine residues on MAPK, thereby modulat-
ing inflammation.36,37 Consistent with other studies, here we 
show that activation of DUSP1 is mediated by upstream activa-
tion of MAP2K1.38,39 Several studies have shown the depend-
ence on DUSP1 induction, including 2 anti-inflammatory 
cytokine drugs (interleukin 10 and transforming growth factor 
β), corticosteroids, and rapamycin.40–42 The data in this study 
identify the potential role of DUSP1 and the required upstream 
mediator MAP2K1 and further suggest that CDDO-Im may 
initiate its cytoprotective effects through similar signaling pre-
cursors as other anti-inflammatory compounds.
The model as presented in this study addresses several limi-
tations that often exist in much of current gene expression 
research to date. First, researchers often focus on a single or 
final time point alone and fail to take full advantage of the 
temporal nature of genes over time.43,44 Understanding the 
transcriptional kinetics provided by time-course studies allows 
for more accurate profiling of not just a single gene but sets of 
related genes that potentially offer greater significance when 
studied from a series of time points. Second, using a multi-
leveled approach such as the one presented here offers better 
understanding into the underlying mechanisms responsible for 
observed responses.45 The integration of programs such as 
X2K takes expression data one step further and allows for iden-
tification of regulatory mechanisms upstream of gene expres-
sion. Although this study highlights a novel approach for 
identification of upstream initiators of observed cytoprotection 
from CDDO-Im treatment, it is not without its own limita-
tions. As shown in Table 2 and other data in this study, defining 
the “intermediate” response of any particular gene over time is 
Figure 5. Network of genes constructed by GeneMANIA software on the 
basis of the functional and biological connectivity of genes. This network 
highlights the genes induced by 1[2-cyano-3,12-dioxooleana-1,9(11)-dien-
28-oyl]imidazole (CDDO-Im) after treatment for 3 hours and represents 
intermediate gene expression response to CDDO-Im. The network is 
graphically represented as nodes (genes) and edges (the biological 
relationship between genes). Black nodes represent significantly 
expressed genes present in the input data submitted to GeneMANIA. 
Gray nodes represent genes returned by GeneMANIA. The size of each 
node is proportional to the degree of connectivity within the network, 
whereas the edge width is proportional to the confidence of the 
connection.
Figure 6. Expression2Kinases network constructed on the basis of the 
transcription factors, protein-protein interactions, and protein kinases 
acting within 30 minutes of treatment with 1[2-cyano-3,12-dioxooleana-
1,9(11)-dien-28-oyl]imidazole . Transcription factor nodes (red), protein-
protein interaction nodes (yellow), and kinase (green). Network generated 
with Cytoscape 3.1.1.
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challenging due to the temporal nature of gene expression and 
limited time point data in a particular time-course study. The 
use of bioinformatics programs such as those used in this study 
is largely based on inferred interactions of experimentally 
derived data. As such, the associated networks and connectivity 
of the data presented are only as good as the databases and lit-
erature that are mined. Future studies exploring the interac-
tions identified in this systems approach are needed to confirm 
the actual roles of key initiators such as MAP2K1 and DUSP1.
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